Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
- Resource Type
- Article
- Source
- In
The Lancet 2006 367(9518):1247-1255 - Subject
Primary Research Articles - Language
- ISSN
- 0140-6736